Long-term Survival Outcomes According to the Pathologic Response After Neoadjuvant Treatment in PDAC and the Fate of the Patients with Good CAP Grade

NCT06630481 · clinicaltrials.gov ↗

COMPLETED

Status

462

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer
Neoadjuvant Therapy
Pathological Complete Response

Interventions

DRUG: neoadjuvant therapy

Sponsor

Seoul National University Hospital